Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway

Stem Cells and Development

Volumn 26, Issue 22, 2017, Pages 1648-1661

  Xu, Lin Lin ^a,b,c   Fu, Hai Xia ^a,b,c   Zhang, Jia Min ^a,b,c   Feng, Fei Er ^a,b,c   Wang, Qian Ming ^a,b,c   Zhu, Xiao Lu ^a,b,c   Xue, Jing ^a,b,c   Wang, Chen Cong ^a,b,c   Chen, Qi ^a,b,c   Liu, Xiao ^a,b,c   Wang, Ya Zhe ^a,b,c   Qin, Ya Zhen ^a,b,c   Kong, Yuan ^a,b,c   Chang, Ying Jun ^a,b,c   Xu, Lan Ping ^a,b,c   Liu, Kai Yan ^a,b,c   Huang, Xiao Jun ^a,b,c   Zhang, Xiao Hui ^a,b,c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Beijing Military Area Command of Chinese PLA   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

all trans retinoic acid; immune thrombocytopenia; mesenchymal stem cells; notch signalling pathway; regulatory dendritic cells

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HEY 1 PROTEIN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; NOTCH 1 INTRACELLULAR DOMAIN; NOTCH1 RECEPTOR; PROTEIN JAGGED 1; RETINOIC ACID; T6 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HES 5; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; NOTCH RECEPTOR;

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOCYTOSIS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; NOTCH SIGNALING; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STEM CELL CULTURE; TH1 CELL; CYTOLOGY; DRUG EFFECT; HEMATOPOIETIC STEM CELL; MESENCHYMAL STROMA CELL; METABOLISM; THROMBOCYTOPENIA;

CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; JAGGED-1 PROTEIN; MESENCHYMAL STROMAL CELLS; RECEPTORS, NOTCH; THROMBOCYTOPENIA; TRETINOIN;

EID: 85033574682     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2017.0078     Document Type: Article

References (71)

1. Toltl LJ, I Nazi, R Jafari and DM Arnold. (2011). Piecing together the humoral and cellular mechanisms of immune thrombocytopenia. Semin Thromb Hemost 37:631-639.
2. Lazarus AH, JW Semple and DB Cines. (2013). Innate and adaptive immunity in immune thrombocytopenia. Semin Hematol 50 (Suppl 1):S68-S70.
3. Ji X, L Zhang, J Peng and M Hou. (2014). T cell immune abnormalities in immune thrombocytopenia. J Hematol Oncol 7:72.
4. Semple JW, D Provan, MB Garvey and J Freedman. (2010). Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 17:590-595.
5. Yazdanbakhsh K, H Zhong and W Bao. (2013). Immune dysregulation in immune thrombocytopenia. Semin Hematol 50 (Suppl 1):S63-S67.
6. Banchereau J, F Briere, C Caux, J Davoust, S Lebecque, YJ Liu, B Pulendran and K Palucka. (2000). Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811.
7. Ueno H, E Klechevsky, R Morita, C Aspord, T Cao, T Matsui, T Di Pucchio, J Connolly, JWFay, et al. (2007). Dendritic cell subsets in health and disease. Immunol Rev 219:118-142.
8. Osorio F, C Fuentes, MN Lopez, F Salazar-Onfray and FE Gonzalez. (2015). Role of dendritic cells in the induction of lymphocyte tolerance. Front Immunol 6:535.
9. Catani L, ME Fagioli, PL Tazzari, F Ricci, A Curti, M Rovito, P Preda, G Chirumbolo, M Amabile, et al. (2006). Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 34:879-887.
10. Catani L, D Sollazzo, S Trabanelli, A Curti, C Evangelisti, N Polverelli, F Palandri, M Baccarani, N Vianelli and RM Lemoli. (2013). Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Ann Hematol 92:67-78.
11. Xu SQ, CY Wang, XJ Zhu, XY Dong, Y Shi, J Peng, P Qin, JZ Sun, C Guo, H Ni and M Hou. (2012). Decreased indoleamine 2, 3-dioxygenase expression in dendritic cells and role of indoleamine 2, 3-dioxygenase-expressing dendritic cells in immune thrombocytopenia. Ann Hematol 91:1623-1631.
12. Yu H, Y Liu, J Han, Z Yang, W Sheng, H Dai, Y Wang, T Xia and M Hou. (2011). TLR7 regulates dendritic celldependent B-cell responses through BlyS in immune thrombocytopenic purpura. Eur J Haematol 86:67-74.
13. Zhou Z, X Li, J Li, C Su, L Zhuang, S Luo and L Zhang. (2010). Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients. J Clin Immunol 30:814-822.
14. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
15. Li N and J Hua. (2017). Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci 74: 2345-2360.
16. Li YP, S Paczesny, E Lauret, S Poirault, P Bordigoni, F Mekhloufi, O Hequet, Y Bertrand, JP Ou-Yang, et al. (2008). Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180:1598-1608.
17. Nauta AJ, AB Kruisselbrink, E Lurvink, R Willemze and WE Fibbe. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocytederived dendritic cells. J Immunol 177:2080-2087.
18. Dokic J, S Tomic, M Markovic, P Milosavljevic and M Colic. (2013). Mesenchymal stem cells from periapical lesions modulate differentiation and functional properties of monocytederived dendritic cells. Eur J Immunol 43:1862-1872.
19. Spaggiari GM, H Abdelrazik, F Becchetti and L Moretta. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576-6583.
20. Wang Z, X Tang, W Xu, Z Cao, L Sun, W Li, Q Li, P Zou and Z Zhao. (2013). The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PLoS One 8:e57470.
21. Zhang B, R Liu, D Shi, X Liu, Y Chen, X Dou, X Zhu, C Lu, W Liang, et al. (2009). Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113:46-57.
22. Zhao ZG, W Xu, L Sun, WM Li, QB Li and P Zou. (2012). The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia. Eur J Cancer 48:1884-1895.
23. Zhang JM, FE Feng, QM Wang, XL Zhu, HX Fu, LP Xu, KY Liu, XJ Huang and XH Zhang. (2016). Plateletderived growth factor-bb protects mesenchymal stem cells (MSCs) derived from immune thrombocytopenia patients against apoptosis and senescence and maintains MSCmediated immunosuppression. Stem Cells Transl Med 5:1631-1643.
24. Provan D, R Stasi, AC Newland, VS Blanchette, P Bolton-Maggs, JB Bussel, BH Chong, DB Cines, TB Gernsheimer, et al. (2010). International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168-186.
25. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
26. Semple JW and J Freedman. (1992). Cellular immune mechanisms in chronic autoimmune thrombocytopenic purpura (ATP). Autoimmunity 13:311-319.
27. Liu J and X Cao. (2015). Regulatory dendritic cells in autoimmunity: a comprehensive review. J Autoimmun 63:1-12.
28. Mougiakakos D, R Jitschin, CC Johansson, R Okita, R Kiessling and K Le Blanc. (2011). The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117:4826-4835.
29. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
30. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
31. Traggiai E, SVolpi, F Schena, MGattorno, F Ferlito, L Moretta and A Martini. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26:562-569.
32. Kim J and P Hematti. (2009). Mesenchymal stem celleducated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 37:1445-1453.
33. Luz-Crawford P, F Djouad, K Toupet, C Bony, M Franquesa, MJ Hoogduijn, C Jorgensen and D Noel. (2016). Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B Cell Differentiation. Stem Cells 34:483-492.
34. Ma J, YN Ning, M Xu, Y Hou, N Wang, XY Hou, YY Yu, H Li, WD He, et al. (2013). Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood 122:2074-2082.
35. Garcia-Gonzalez P, G Ubilla-Olguin, D Catalan, K Schinnerling and JC Aguillon. (2016). Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. Autoimmun Rev 15:1071-1080.
36. Gordon JR, Y Ma, L Churchman, SA Gordon and W Dawicki. (2014). Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol 5:7.
37. Manicassamy S and B Pulendran. (2011). Dendritic cell control of tolerogenic responses. Immunol Rev 241:206-227.
38. Schwartz RH. (2003). T cell anergy. Annu Rev Immunol 21:305-334.
39. Shalev I, M Schmelzle, SC Robson and G Levy. (2011). Making sense of regulatory T cell suppressive function. Semin Immunol 23:282-292.
40. McKenzie CG, L Guo, J Freedman and JW Semple. (2013). Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 163:10-23.
41. Moser M and KM Murphy. (2000). Dendritic cell regulation of TH1-TH2 development. Nat Immunol 1:199-205.
42. Perez-Simon JA, S Tabera, ME Sarasquete, M Diez-Campelo, J Canchado, LI Sanchez-Abarca, B Blanco, I Alberca, C Herrero-Sanchez, C Canizo and JF San Miguel. (2009). Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 11:698-705.
43. Zhang D, H Li, L Ma, X Zhang, F Xue, Z Zhou, Y Chi, X Liu, Y Huang, Y Yang and R Yang. (2014). The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity 47:519-529.
44. Contreras-Cornejo H, G Saucedo-Correa, J Oviedo-Boyso, JJ Valdez-Alarcon, VM Baizabal-Aguirre, M Cajero-Juarez and A Bravo-Patino. (2016). The CSL proteins, versatile transcription factors and context dependent corepressors of the notch signaling pathway. Cell Div 11:12; eCollection 2016.
45. Ilagan MX and R Kopan. (2007). SnapShot: notch signaling pathway. Cell 128:1246.
46. Wu J and EH Bresnick. (2007). Bare rudiments of notch signaling: how receptor levels are regulated. Trends Biochem Sci 32:477-485.
47. Kopan R and MX Ilagan. (2009). The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216-233.
48. Iso T, L Kedes and Y Hamamori. (2003). HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194:237-255.
49. Fan JZ, L Yang, GL Meng, YS Lin, BY Wei, J Fan, HM Hu, YW Liu, S Chen, et al. (2014). Estrogen improves the proliferation and differentiation of hBMSCs derived from postmenopausal osteoporosis through notch signaling pathway. Mol Cell Biochem 392:85-93.
50. Ugarte F, M Ryser, S Thieme, FA Fierro, K Navratiel, M Bornhauser and S Brenner. (2009). Notch signaling enhances osteogenic differentiation while inhibiting adipogenesis in primary human bone marrow stromal cells. Exp Hematol 37:867-875. e1.
51. Dong Y, T Long, C Wang, AJ Mirando, J Chen, RJ O'Keefe and MJ Hilton. (2014). NOTCH-mediated maintenance and expansion of human bone marrow stromal/ stem cells: a technology designed for orthopedic regenerative medicine. Stem Cells Transl Med 3:1456-1466.
52. Wang YC, SHWang, YN Wei, DW Du, H Xu, CC Gao, MH Zheng, J Xie, JC Li, et al. (2013). Notch-RBP-J signaling is required by bone marrow stromal cells for the treatment of acute graft versus host disease. Stem Cell Res 11:721-735.
53. Na T, J Liu, K Zhang, M Ding and BZ Yuan. (2015). The notch signaling regulates CD105 expression, osteogenic differentiation and immunomodulation of human umbilical cord mesenchymal stem cells. PLoS One 10:e0118168.
54. Cheng P, Y Nefedova, CA Corzo and DI Gabrilovich. (2007). Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood 109:507-515.
55. Ohishi K, B Varnum-Finney, RE Serda, C Anasetti and ID Bernstein. (2001). The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells. Blood 98:1402-1407.
56. Hoshino N, N Katayama, T Shibasaki, K Ohishi, J Nishioka, M Masuya, Y Miyahara, M Hayashida, D Shimomura, et al. (2005). A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes. J Leukoc Biol 78:921-929.
57. Cheng P, Y Nefedova, L Miele, BA Osborne and D Gabrilovich. (2003). Notch signaling is necessary but not sufficient for differentiation of dendritic cells. Blood 102:3980-3988.
58. Liotta F, R Angeli, L Cosmi, L Fili, C Manuelli, F Frosali, B Mazzinghi, L Maggi, A Pasini, et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrowderived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26:279-289.
59. Shi D, L Liao, B Zhang, R Liu, X Dou, J Li, X Zhu, L Yu, D Chen and RC Zhao. (2011). Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-kappaB signaling. Exp Hematol 39:214-224. e1.
60. Cahill EF, LM Tobin, F Carty, BP Mahon and K English. (2015). Jagged-1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther 6:19.
61. Foldi J, AY Chung, H Xu, J Zhu, HH Outtz, J Kitajewski, Y Li, X Hu and LB Ivashkiv. (2010). Autoamplification of Notch signaling in macrophages by TLR-induced and RBP-Jdependent induction of Jagged1. J Immunol 185:5023-5031.
62. Manderfield LJ, FA High, KA Engleka, F Liu, L Li, S Rentschler and JA Epstein. (2012). Notch activation of Jagged1 contributes to the assembly of the arterial wall. Circulation 125:314-323.
63. Hall JA, JR Grainger, SP Spencer and Y Belkaid. (2011). The role of retinoic acid in tolerance and immunity. Immunity 35:13-22.
64. Iwata M, Y Eshima and H Kagechika. (2003). Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol 15:1017-1025.
65. Xiao S, H Jin, T Korn, SM Liu, M Oukka, B Lim and VK Kuchroo. (2008). Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 181:2277-2284.
66. Bhatt S, J Qin, C Bennett, S Qian, JJ Fung, TA Hamilton and L Lu. (2014). All-trans retinoic acid induces arginase-1 and inducible nitric oxide synthase-producing dendritic cells with T cell inhibitory function. J Immunol 192:5098-5108.
67. Huang ME, YC Ye, SR Chen, JR Chai, JX Lu, L Zhoa, LJ Gu and ZY Wang. (1988). Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572.
68. Kinoshita K, BS Yoo, Y Nozaki, M Sugiyama, S Ikoma, M Ohno, M Funauchi and A Kanamaru. (2003). Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J Immunol 170:5793-5798.
69. Kwok SK, MK Park, ML Cho, HJ Oh, EM Park, DG Lee, J Lee, HY Kim and SH Park. (2012). Retinoic acid attenuates rheumatoid inflammation in mice. J Immunol 189:1062-1071.
70. Van YH, WH Lee, S Ortiz, MH Lee, HJ Qin and CP Liu. (2009). All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferongamma-producing T-cells without affecting Th17 cells. Diabetes 58:146-155.
71. Dai L, R Zhang, Z Wang, Y He, X Bai, M Zhu, Z Yu and CG Ruan. (2016). Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia. Thromb Res 140:73-80.